News articles about Bioverativ (NASDAQ:BIVV) have trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bioverativ earned a news impact score of 0.20 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.4725009728847 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment’s analysis:
- Bordering on Key Levels: Bioverativ Inc. (BIVV), Avon Products, Inc. (AVP) – Market Movers (financialqz.com)
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Into Whether the Sale of Bioverativ Inc. to Sanofi for $105 Per Share is Fair to Shareholders – BIVV (finance.yahoo.com)
- Bioverativ Inc (BIVV) Expected to Post Quarterly Sales of $325.89 Million (americanbankingnews.com)
- Zacks: Analysts Anticipate Bioverativ Inc (BIVV) to Post $0.89 Earnings Per Share (americanbankingnews.com)
Shares of Bioverativ (NASDAQ:BIVV) traded down $0.49 during trading on Monday, reaching $103.50. The company had a trading volume of 3,091,397 shares, compared to its average volume of 3,335,938. The company has a market capitalization of $11,230.00 and a price-to-earnings ratio of 25.31. Bioverativ has a 1 year low of $41.88 and a 1 year high of $104.30.
BIVV has been the topic of several recent analyst reports. Zacks Investment Research upgraded Bioverativ from a “hold” rating to a “strong-buy” rating and set a $69.00 price target on the stock in a research note on Thursday, October 19th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $71.00 price target on shares of Bioverativ in a research note on Monday, October 23rd. Deutsche Bank set a $53.00 price target on Bioverativ and gave the stock a “hold” rating in a research note on Monday, November 20th. Jefferies Group boosted their price target on Bioverativ to $79.00 and gave the stock a “buy” rating in a research note on Thursday, January 18th. Finally, Credit Suisse Group reiterated a “neutral” rating and issued a $65.00 price target on shares of Bioverativ in a research note on Thursday, January 18th. Thirteen equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $62.86.
TRADEMARK VIOLATION WARNING: This report was first posted by Stock Observer and is the property of of Stock Observer. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.thestockobserver.com/2018/02/05/bioverativ-bivv-earning-somewhat-positive-news-coverage-report-shows.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.